AR126029A1 - LIGANDOS DE PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EL RECEPTOR DE TRANSFERRINA 1 (TfR1) - Google Patents
LIGANDOS DE PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EL RECEPTOR DE TRANSFERRINA 1 (TfR1)Info
- Publication number
- AR126029A1 AR126029A1 ARP210103150A ARP210103150A AR126029A1 AR 126029 A1 AR126029 A1 AR 126029A1 AR P210103150 A ARP210103150 A AR P210103150A AR P210103150 A ARP210103150 A AR P210103150A AR 126029 A1 AR126029 A1 AR 126029A1
- Authority
- AR
- Argentina
- Prior art keywords
- multimeric binding
- tfr1
- peptide
- peptide ligands
- peptide ligand
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 16
- 239000003446 ligand Substances 0.000 title abstract 10
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 title abstract 5
- 102000007238 Transferrin Receptors Human genes 0.000 title abstract 2
- 108010033576 Transferrin Receptors Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000002062 molecular scaffold Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a polipéptidos que se unen covalentemente a armazones moleculares de manera que dos o más bucles de péptidos se subtienden entre los puntos de unión al armazón. En particular, la invención describe péptidos que se unen a TfR1. La invención también se refiere a complejos de unión multiméricos que comprenden al menos dos de dichos ligandos peptídicos bicíclicos. La invención también incluye composiciones farmacéuticas que comprenden dichos ligandos peptídicos y complejos de unión multiméricos y el uso de dichos ligandos peptídicos y complejos de unión multiméricos y composiciones farmacéuticas para prevenir, suprimir o tratar una enfermedad o trastorno mediante la administración de un agente terapéutico mediada por TfR1. Reivindicación 1: Un ligando peptídico específico para el receptor de transferrina 1 (TfR1) que comprende un polipéptido que comprende al menos tres grupos reactivos, separados por al menos dos secuencias de bucle, y un andamio molecular que forma enlaces covalentes con los grupos reactivos del polipéptido de manera que al menos se forman dos bucles polipeptídicos en el armazón molecular. Reivindicación 2: El ligando peptídico de acuerdo con la reivindicación 1, en donde dichos grupos reactivos comprenden residuos de cisteína. Reivindicación 4: El ligando peptídico de acuerdo con cualquiera de las reivindicaciones 1 a 3, en donde dichas secuencias de bucle comprenden 2, 3, 6, 8 o 9 aminoácidos. Reivindicación 14: Un complejo de unión multimérico que comprende al menos dos de los ligandos peptídicos según cualquiera de las reivindicaciones 1 a 13. Reivindicación 15: Complejo de unión multimérico según la reivindicación 14, que comprende un compuesto de fórmula (1), en donde CHM representa un resto de bisagra central; biciclo representa un ligando peptídico bicíclico según cualquiera de las reivindicaciones 1 a 13; y m representa un número entero seleccionado de 2 a 10, como 2, 3 o 4. Reivindicación 16: Complejo de unión multimérico según la reivindicación 15, en donde m representa 2 y CHM es un motivo de fórmula (A), como BCY19409. Reivindicación 18: El ligando peptídico de acuerdo con cualquiera de las reivindicaciones 1 a 13, o el complejo de unión multimérico de acuerdo con cualquiera de las reivindicaciones 14 a 16, o la composición farmacéutica de la reivindicación 17, para su uso en la prevención, supresión o tratamiento de una enfermedad o trastorno a través de la administración de un agente terapéutico mediada por TfR1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2017927.1A GB202017927D0 (en) | 2020-11-13 | 2020-11-13 | Bicyclic peptide ligands specific for transferrin |
| GBGB2106903.4A GB202106903D0 (en) | 2021-05-14 | 2021-05-14 | Bicycle peptide ligands specific for transferrin |
| US202163261820P | 2021-09-29 | 2021-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126029A1 true AR126029A1 (es) | 2023-09-06 |
Family
ID=81600834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103150A AR126029A1 (es) | 2020-11-13 | 2021-11-12 | LIGANDOS DE PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EL RECEPTOR DE TRANSFERRINA 1 (TfR1) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11970555B2 (es) |
| EP (1) | EP4244235A1 (es) |
| JP (1) | JP2023549229A (es) |
| KR (1) | KR20230107589A (es) |
| CN (1) | CN116802190A (es) |
| AR (1) | AR126029A1 (es) |
| AU (1) | AU2021376917A1 (es) |
| CA (1) | CA3201414A1 (es) |
| IL (1) | IL302713A (es) |
| MX (1) | MX2023005624A (es) |
| TW (1) | TW202233664A (es) |
| WO (1) | WO2022101633A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3201414A1 (en) | 2020-11-13 | 2022-05-19 | Bicycletx Limited | Bicyclic peptide ligands specific for transferrin receptor 1 (tfr1) |
| GB202206431D0 (en) * | 2022-05-03 | 2022-06-15 | Bicycletx Ltd | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2474613T3 (da) | 2008-02-05 | 2014-10-06 | Bicycle Therapeutics Ltd | Fremgangsmåder og sammensætninger |
| EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| CN104650186A (zh) * | 2015-03-09 | 2015-05-27 | 中国药科大学 | 一种能够与TfR1特异性结合的活性肽及其应用 |
| GB201706477D0 (en) * | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| WO2018197893A1 (en) | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| US10875894B2 (en) * | 2018-02-23 | 2020-12-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| EP3870597A1 (en) * | 2018-10-23 | 2021-09-01 | BicycleTx Limited | Bicyclic peptide ligands and uses thereof |
| US20220306689A9 (en) * | 2018-12-21 | 2022-09-29 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201912320D0 (en) * | 2019-08-28 | 2019-10-09 | Bicycletx Ltd | PBP Binding Bicyclic Peptide Ligands |
| CA3201414A1 (en) | 2020-11-13 | 2022-05-19 | Bicycletx Limited | Bicyclic peptide ligands specific for transferrin receptor 1 (tfr1) |
-
2021
- 2021-11-12 CA CA3201414A patent/CA3201414A1/en active Pending
- 2021-11-12 AR ARP210103150A patent/AR126029A1/es unknown
- 2021-11-12 JP JP2023528449A patent/JP2023549229A/ja active Pending
- 2021-11-12 WO PCT/GB2021/052927 patent/WO2022101633A1/en active Application Filing
- 2021-11-12 MX MX2023005624A patent/MX2023005624A/es unknown
- 2021-11-12 IL IL302713A patent/IL302713A/en unknown
- 2021-11-12 EP EP21819173.2A patent/EP4244235A1/en active Pending
- 2021-11-12 TW TW110142158A patent/TW202233664A/zh unknown
- 2021-11-12 US US17/454,665 patent/US11970555B2/en active Active
- 2021-11-12 CN CN202180089518.5A patent/CN116802190A/zh active Pending
- 2021-11-12 KR KR1020237017137A patent/KR20230107589A/ko unknown
- 2021-11-12 AU AU2021376917A patent/AU2021376917A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3201414A1 (en) | 2022-05-19 |
| KR20230107589A (ko) | 2023-07-17 |
| US20220194988A1 (en) | 2022-06-23 |
| CN116802190A (zh) | 2023-09-22 |
| JP2023549229A (ja) | 2023-11-22 |
| AU2021376917A1 (en) | 2023-06-29 |
| MX2023005624A (es) | 2023-05-24 |
| US11970555B2 (en) | 2024-04-30 |
| EP4244235A1 (en) | 2023-09-20 |
| TW202233664A (zh) | 2022-09-01 |
| IL302713A (en) | 2023-07-01 |
| WO2022101633A1 (en) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126029A1 (es) | LIGANDOS DE PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EL RECEPTOR DE TRANSFERRINA 1 (TfR1) | |
| PH12020552179A1 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| BR112021022315A2 (pt) | Ligantes de peptídeo bicíclicos específicos para ox40 | |
| JP7219258B2 (ja) | ペプチド模倣大環状分子およびその製剤 | |
| MX2020008791A (es) | Ligandos de peptidos biciclicos multimericos. | |
| PH12020550929A1 (en) | Bicyclic peptide ligands specific for epha2 | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| JP2018503668A5 (es) | ||
| PE20181852A1 (es) | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles | |
| UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
| PE20190436A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 | |
| NZ731185A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
| US10039807B2 (en) | bFGF-polymer conjugates, methods for making the same and applications thereof | |
| JP2016521256A5 (es) | ||
| HRP20160020T1 (hr) | Postupak za aktiviranje pomagaäśke t stanice i pripravak za uporabu u postupku | |
| Kim et al. | Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors | |
| BR112022007099A2 (pt) | Conjugados de fármaco de ligante de peptídeo bicíclico | |
| WO2014104974A2 (en) | Self-assembling ultrashort peptides modified with bioactive agents by click chemistry | |
| EA202192555A1 (ru) | Комбинированная терапия для лечения рака | |
| JPWO2021019243A5 (es) | ||
| JP2018521977A5 (es) | ||
| AR115601A1 (es) | Ligandos peptídicos bicíclicos específicos para nectina-4 | |
| EA202190104A1 (ru) | Бициклические пептидные лиганды, специфичные к нектину-4 | |
| TW202216204A (zh) | Vegf結合肽 | |
| EA202091991A1 (ru) | Мультимерные бициклические пептидные лиганды |